Past history, present status and future prospect of cancer immunotherapy adopting chimeric antigen receptor-T lymphocytes
Alex Hongsheng CHANG
Abstract：Clinical trials adopting chimeric antigen receptor -T lymphocytes (CAR-T) have made a breakthrough in treatment of B lymphocytic leukemia .Several clinical research centers in USA have reported excellent clinical response rate of 60%- 80% in these group of patients.This in turn drives a new wave of enthusiasm in immunotherapy , and comes along with interests and invest -ment from big pharmaceutical companies ,as well as investment firms.In order for immunotherapy to make a major impact in cancer therapy , it is required not only to enhance its effectiveness , but also to increase its variety.We believe, with more and more interests in translational medical research , the 21 Century will be an era that immunotherapy enters the center stage of cancer therapy .
Keywords：Chimeric antigen receptor(CAR)T cellTumorImmune therapy
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 129-133 )